Since its establishment in 1985, the company has been continuously cultivating the field of in vitro diagnostics, positioning itself as a "first-class domestic immune diagnostic technology enterprise", and maintaining industry technological leadership through research and development investment. The company has established a complete R&D system in accordance with the requirements of ISO13485 standard and has passed TUV Rheinland certification. More than 25% of senior professional and technical personnel have rich experience and theoretical foundation, forming a research and development team with knowledge and specialization as the core.

The company has established a research and development platform covering the fields of biological raw materials, radioimmunoassay, enzyme-linked immunosorbent assay, colloidal gold, chemiluminescence, etc. Its product line involves more than 300 diagnostic reagents in more than ten categories such as thyroid function, tumors, and cardiovascular diseases, forming a business layout that spans the upstream and downstream industrial chain. The company currently has 11 invention patents and 2 utility model patents. It is a high-tech enterprise and a specialized and innovative small and medium-sized enterprise in Beijing. After more than 30 years of technological accumulation, the company's biological raw material technology platform has obvious technical advantages in the preparation of monoclonal antibodies, especially in the preparation of small molecule monoclonal antibodies. There are nearly 60 mature and widely used monoclonal antibodies for production and scientific research. The project of "Development and Preparation Technology of Small Molecule Peptide Monoclonal Antibodies" has won the second prize of provincial and ministerial level scientific and technological progress.

As one of the earliest enterprises in China engaged in the research and development, production, and sales of radioimmune diagnostic reagents, the company has a complete product line and a long-term leading market share. Among them, the Triiodothyronine Radioimmunoassay Diagnostic Kit won the National Quality Silver Award. The company continues to focus on optimizing labeling methods and collaborates with universities, research institutions, and other institutions to develop various new iodine-125 markers. On platforms such as enzyme immunoassay and chemiluminescence, the company adheres to the research and development model of "fully independent intellectual property rights", and its core technologies include magnetic particle antigen/antibody coupling technology, acridine ester labeling technology, FITC universal labeling technology, and color/substrate systems. For products such as Jia Gong and hypertension, the company has independently developed and obtained invention patents for small molecule labeling technology, which can significantly improve the detection performance of the products. The sensitivity, stability, and specificity indicators are among the top in the industry. The company has independently developed and obtained invention patents for the excitation liquid and pre excitation liquid, which are registered as separate products. The system is stable, with low corrosiveness to the instrument's pipeline system, low background and stable performance. The price is cheap, easy to prepare, and the cost advantage is obvious.